Open AccessThis article is
- freely available
Molecular Therapies in Thyroid Cancer
Northwestern University, Feinberg School of Medicine, Division of Hematology/ Oncology, Department of Medicine, 676 North St. Clair Street, Suite 850, Chicago, IL 60611, USA
* Author to whom correspondence should be addressed.
Received: 2 November 2010; in revised form: 9 December 2010 / Accepted: 22 December 2010 / Published: 24 December 2010
Abstract: Thyroid cancer is a common diagnosis with greater than 34,000 cases per year in the United States. Early stage thyroid cancer is often managed with surgical intervention and radioactive iodine; however, for recurrent or metastatic disease, the treatment options, historically, have been limited to chemotherapy. Chemotherapy for metastatic thyroid cancer has been of limited efficacy. Encouragingly, molecular therapeutics have played a greater role in managing patients with advanced disease. These agents work primarily through disruption of tyrosine kinase pathways. This review will discuss the expanding role of molecular targets in managing patients with advanced thyroid cancer.
Keywords: advanced thyroid cancer; molecular therapy; tyrosine kinase inhibitors
Article StatisticsClick here to load and display the download statistics.
Notes: Multiple requests from the same IP address are counted as one view.
Cite This Article
MDPI and ACS Style
Huyck, T.; Agulnik, M. Molecular Therapies in Thyroid Cancer. Pharmaceuticals 2011, 4, 91-100.
Huyck T, Agulnik M. Molecular Therapies in Thyroid Cancer. Pharmaceuticals. 2011; 4(1):91-100.
Huyck, Timothy; Agulnik, Mark. 2011. "Molecular Therapies in Thyroid Cancer." Pharmaceuticals 4, no. 1: 91-100.